Mindpeak Secures First Patent for Advanced AI in Digital Pathology

We’re proud to introduce PhenoScout AI, our next-generation multiplex immunofluorescence (mIF) analysis solution.

By automating phenotype identification, biomarker quantification, and spatial readouts, PhenoScout AI reduces variability and supports large-scale studies. The solution is designed for pharma, diagnostics, and academic research to accelerate translational medicine.

👉 Learn more

‍

We are delighted to announce that Christiaan Neeleman has joined Mindpeak’s Board of Directors.

With more than 20 years of international leadership experience in life sciences, diagnostics, and health technology - including senior roles at Discovery Life Sciences, Definiens, and Philips Healthcare - Christiaan brings deep expertise that will help accelerate our global expansion.

His proven track record in biomarker development, companion diagnostics, and scaling precision diagnostics businesses aligns perfectly with Mindpeak’s mission: enabling faster, more accurate cancer diagnostics through AI-powered pathology.

We are excited to collaborate with Christiaan as we strengthen partnerships, expand into new markets, and further drive the adoption of AI across clinical and research settings.

Read the full press release here

‍

‍

At Mindpeak, our vision is clear: world-class AI diagnostics should be available to every pathology lab, everywhere. By partnering with leading technology providers, we’re removing barriers to adoption and making AI-powered precision diagnostics a practical reality for labs worldwide.

Seamless AI Integration with Pathomation

Through our strategic collaboration with Pathomation, a globally trusted provider of digital pathology platforms, Mindpeak’s CE-IVD certified AI algorithms – including Ki-67, HER2, and zero-click PD-L1 scoring across multiple tissue types – are now natively integrated into Pathomation’s solutions.

This partnership means laboratories can:

• Adopt advanced AI instantly – No extra development, integrations, or technical overhead required.
• Work within existing workflows – Our algorithms run directly inside Pathomation’s widely adopted platform.
• Deliver faster, more consistent results – Helping pathologists make confident, high-quality diagnostic decisions for patients everywhere.
  
  

Reaching More Labs, Globally

Pathomation’s worldwide presence, with distributor networks and users spanning Europe, Asia, and Latin America, ensures that AI-powered image analysis is accessible to more labs and more patients across the globe. Together, we’re removing geographic and technical barriers to bring state-of-the-art diagnostics to every corner of the world.

“Every partnership we form moves us closer to our goal: AI-powered image analysis in every lab, for every patient. Our collaboration with Pathomation is an important step toward making this vision a reality.” – Felix Faber, CEO, Mindpeak

‍

🔗 Learn more about the partnership and read the full press release: https://tissuepathology.com/2025/08/21/pathomation-and-mindpeak-forge-strategic-partnership-to-accelerate-ai-adoption-in-digital-pathology-workflows/

‍

‍